GlassScriptPhysician profile
Michael Gary Lehman
NPI 1427080076
$1,017.97
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $306 · 2020: $301 · 2021: $155 · 2022: $256.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $333.66 | 2020-2022 | |
| Celgene Corporation | $173.82 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $120.97 | 2019-2021 | |
| Galderma Laboratories, L.P. | $111.20 | 2019-2020 | |
| Genentech USA, INC. | $86.18 | 2020 | |
| Abbvie INC. | $38.38 | 2022 | |
| Leo Pharma INC. | $29.61 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $27.20 | 2022 | |
| Genzyme Corporation | $22.19 | 2019 | |
| Vyne Pharmaceuticals INC. | $21.51 | 2020 | |
| Dermira, INC. | $20.71 | 2020 | |
| Janssen Biotech, INC. | $19.56 | 2021 | |
| Journey Medical Corporation | $12.98 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lehman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.